Saccharomyces boulardii CNCM I-745 in different clinical conditions. - Wikidata - wikimedia - TriplyDB

Saccharomyces boulardii CNCM I-745 in different clinical conditions.

Saccharomyces boulardii CNCM I-745 in different clinical conditions.

http://www.wikidata.org/entity/Q38226331

about

Vaccine against Helicobacter pylori: Inevitable approach Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.The effects of probiotics on treatment of Helicobacter pylori eradication in children.Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran.Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea.Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients.Saccharomyces boulardii CNCM I-745 Improves Intestinal Enzyme Function: A Trophic Effects Review.Time Series Analysis of the Microbiota of Children Suffering From Acute Infectious Diarrhea and Their Recovery After Treatment.

P2860

Q26752743-F01C4CC0-9D0C-4523-8499-227FA279CB82 Q26752760-C1730320-EC40-41F8-BD6F-49C6712BADAC Q26796416-5920E6C6-952E-4564-B937-0DD8296FAB45 Q28066899-32B599D4-9833-47BD-9ACD-1350538A4CD5 Q33466435-2280D30F-B861-4996-85A2-15EE6FC459F6 Q35236908-45BA0493-AEB1-4312-AA4E-E480B82EB3E5 Q36521636-195FCEA5-732D-4DDD-B055-F511B15DDB08 Q36683562-B555D5F1-D0F2-44BE-924C-11CC2F8D9939 Q41502760-DE9AAF23-DC65-4EA6-BB67-AEDF6B455F75 Q46300594-47010A37-821D-42D6-890D-2854701E53AB Q49957312-848705CE-8BB7-4C61-BFF0-7102932C0AA1 Q55396690-79EA6D1E-DFED-4D4F-A402-8DFA6BC633EE

P2860

Saccharomyces boulardii CNCM I-745 in different clinical conditions.

http://www.wikidata.org/entity/Q38226331

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Saccharomyces boulardii CNCM I-745 in different clinical conditions.

@en

type

label

Saccharomyces boulardii CNCM I-745 in different clinical conditions.

@en

prefLabel

Saccharomyces boulardii CNCM I-745 in different clinical conditions.

@en

P1433

Q38226331-132FC90E-8729-4F3F-BB0D-F8BEC6E0478D

P1476

Q38226331-66C183C6-00A8-4538-B586-C527F11846F5

P2093

Q38226331-0CCB5102-9E8A-4095-A941-174E25D27689

Q38226331-7EA31092-3AD6-4316-AA2A-32BD1E99162E

Q38226331-AE6A94B6-E167-45C3-9933-1397CAA4FEC0

Q38226331-FB8DC7B0-F60C-4798-9345-40C0C76FE8C7

P2860

Q38226331-1AEDEDFD-4CD3-4A67-B086-39F1069CD271

Q38226331-1F0F521A-FB5F-4C45-B48D-E47626170EC5

Q38226331-1F37730A-73F2-4A66-9C37-51797C81A047

Q38226331-20D57825-6B0E-479C-AC26-B8D21249071A

Q38226331-2216B579-E6B0-41B1-9826-0B7B56B7E399

Q38226331-22C44349-7A05-4D97-9DB2-8262EDCCDB10

Q38226331-31FAF582-B784-4642-B006-3D1265FD3AB4

Q38226331-35850477-E608-4E54-99DD-7F6AB82AF064

Q38226331-38EC9CD0-2FBD-4CD2-9D6E-39FF52018499

Q38226331-3F00D798-1B7E-44E3-BAE1-C5C0C800BBA1

P304

Q38226331-E3163E8A-FDDE-4E23-BC3F-39A8C69B3709

P31

Q38226331-A568C005-478E-4798-8D01-9C9D7A9B3E84

P356

Q38226331-18969D87-FF59-4524-9BDC-79008D31469F

P407

Q38226331-7EE821B7-3094-4582-A188-C48543D5A524

P433

Q38226331-B449D38F-CB05-4F52-94D6-52603F1FE446

P478

Q38226331-E14F69DE-A4CA-4923-8FFF-02F96E35DA8B

P577

Q38226331-307B10CD-B891-410D-91BA-8A031FB655C5

P698

Q38226331-59D977A7-11ED-48A7-B19D-D7CCDD378299

P356

14712598.2014.937419

P1433

Expert Opinion on Biological Therapy

P1476

Saccharomyces boulardii CNCM I-745 in different clinical conditions.

@en

P2093

Ates Kara

http://www.w3.org/2001/XMLSchema#string

Ener Cagri Dinleyici

http://www.w3.org/2001/XMLSchema#string

Metehan Ozen

http://www.w3.org/2001/XMLSchema#string

Yvan Vandenplas

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review and meta-analysis of Saccharomyces boulardii in adult patients

Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations

Saccharomyces boulardii in maintenance treatment of Crohn's disease

A pilot trial of Saccharomyces boulardii in ulcerative colitis

Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial

Effects of Saccharomyces boulardii in children with acute diarrhoea

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection

A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life

Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment

P304

1593-1609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2014.937419

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24995675

http://www.w3.org/2001/XMLSchema#string